Loading…
Disease duration, hypertension and medication requirements are associated with organ damage in childhood-onset systemic lupus erythematosus
To investigate the frequency of organ damage in childhood-onset systemic lupus erythematosus (SLE) and to identify disease variables and patient characteristics related to organ damage. A cohort of 71 patients was examined in a cross-sectional study after a mean disease duration of 10.8+/-8.2 years...
Saved in:
| Published in: | Clinical and experimental rheumatology 2005-03, Vol.23 (2), p.261-269 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 269 |
| container_issue | 2 |
| container_start_page | 261 |
| container_title | Clinical and experimental rheumatology |
| container_volume | 23 |
| creator | LILLEBY, V FLATØ, B FØRRE, Ø |
| description | To investigate the frequency of organ damage in childhood-onset systemic lupus erythematosus (SLE) and to identify disease variables and patient characteristics related to organ damage.
A cohort of 71 patients was examined in a cross-sectional study after a mean disease duration of 10.8+/-8.2 years (mean age 26.4+/-9.8 years). The occurrence of organ damage was measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Factors analysed as possible explanatory variables of organ damage were the following: demographic variables, clinical variables at diagnosis and during disease course, as well as medication use. Growth and self-reported health status were also measured.
The most frequent areas of organ damage were in the neuropsychiatric (28%), renal (13%) and musculoskeletal (13%) organ systems. Forty-three patients (61%) had evidence of damage. The mean SDI score was 1.3 for the whole study population. Hypertension, longer disease duration and use of cyclophosphamide were factors significantly related to an increasing SDI score in multiple linear regression analyses. Furthermore, patients with damage (SDI > or =1) compared to those without damage (SDI = 0) had a significantly higher cumulative corticosteroid dose (24.7 g versus 10.6 g) and more frequently required high-dose prednisolone at diagnosis (68% versus 43%).
Evidence of organ damage was found in 61% of all patients. Long disease duration, known hypertension and use of cylophosphamide were significantly associated with an increasing SDI score. Furthermore high-dose prednisolone at diagnosis and cumulative prednisolone dose were significantly related to the presence of organ damage. |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_15895902</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15895902</sourcerecordid><originalsourceid>FETCH-LOGICAL-p239t-4c1857d1efb29a2c54672c341a0cb8d7e856e6a90261ae256fa6a45282de445e3</originalsourceid><addsrcrecordid>eNpFkMtKxDAUhoMozjj6CpKNOwtN2qTpUsYrDLhRmN1wJjmdRnozJ0X6DL60xQuuDj__xw_fOWJLocosSUuzPWbLNCtlYpTeLtgZ0VuaSq10ccoWQplSlalcss9bTwiE3I0Bou-7a15PA4aIHc2JQ-d4i87b75IHfB99wBa7SBwCciDqrYeIjn_4WPM-HKDjDlo4IPcdt7VvXN33Luk7wshpooitt7wZh5E4hinW2ELsaaRzdlJBQ3jxe1fs9f7uZf2YbJ4fntY3m2SQWRmT3AqjCiew2ssSpFW5LqTNcgGp3RtX4GyMGmY9LQCl0hVoyJU00mGeK8xW7PJndxj3s9tuCL6FMO3-vjIDV78AkIWmCtBZT_-cNqnIhMm-ADX7cKw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Disease duration, hypertension and medication requirements are associated with organ damage in childhood-onset systemic lupus erythematosus</title><source>Freely Accessible Journals</source><creator>LILLEBY, V ; FLATØ, B ; FØRRE, Ø</creator><creatorcontrib>LILLEBY, V ; FLATØ, B ; FØRRE, Ø</creatorcontrib><description>To investigate the frequency of organ damage in childhood-onset systemic lupus erythematosus (SLE) and to identify disease variables and patient characteristics related to organ damage.
A cohort of 71 patients was examined in a cross-sectional study after a mean disease duration of 10.8+/-8.2 years (mean age 26.4+/-9.8 years). The occurrence of organ damage was measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Factors analysed as possible explanatory variables of organ damage were the following: demographic variables, clinical variables at diagnosis and during disease course, as well as medication use. Growth and self-reported health status were also measured.
The most frequent areas of organ damage were in the neuropsychiatric (28%), renal (13%) and musculoskeletal (13%) organ systems. Forty-three patients (61%) had evidence of damage. The mean SDI score was 1.3 for the whole study population. Hypertension, longer disease duration and use of cyclophosphamide were factors significantly related to an increasing SDI score in multiple linear regression analyses. Furthermore, patients with damage (SDI > or =1) compared to those without damage (SDI = 0) had a significantly higher cumulative corticosteroid dose (24.7 g versus 10.6 g) and more frequently required high-dose prednisolone at diagnosis (68% versus 43%).
Evidence of organ damage was found in 61% of all patients. Long disease duration, known hypertension and use of cylophosphamide were significantly associated with an increasing SDI score. Furthermore high-dose prednisolone at diagnosis and cumulative prednisolone dose were significantly related to the presence of organ damage.</description><identifier>ISSN: 0392-856X</identifier><identifier>EISSN: 1593-098X</identifier><identifier>PMID: 15895902</identifier><language>eng</language><publisher>Pisa: Clinical and Experimental Rheumatology</publisher><subject>Adolescent ; Age of Onset ; Biological and medical sciences ; Cross-Sectional Studies ; Cyclophosphamide - adverse effects ; Cyclophosphamide - therapeutic use ; Female ; Glucocorticoids - therapeutic use ; Health Status ; Humans ; Hypertension - etiology ; Hypertension - pathology ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - therapeutic use ; Lupus Nephritis - epidemiology ; Lupus Nephritis - etiology ; Lupus Nephritis - pathology ; Lupus Vasculitis, Central Nervous System - epidemiology ; Lupus Vasculitis, Central Nervous System - etiology ; Lupus Vasculitis, Central Nervous System - pathology ; Male ; Medical sciences ; Musculoskeletal Diseases - epidemiology ; Musculoskeletal Diseases - etiology ; Musculoskeletal Diseases - pathology ; Norway - epidemiology ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Severity of Illness Index ; Time Factors</subject><ispartof>Clinical and experimental rheumatology, 2005-03, Vol.23 (2), p.261-269</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16801318$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15895902$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LILLEBY, V</creatorcontrib><creatorcontrib>FLATØ, B</creatorcontrib><creatorcontrib>FØRRE, Ø</creatorcontrib><title>Disease duration, hypertension and medication requirements are associated with organ damage in childhood-onset systemic lupus erythematosus</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>To investigate the frequency of organ damage in childhood-onset systemic lupus erythematosus (SLE) and to identify disease variables and patient characteristics related to organ damage.
A cohort of 71 patients was examined in a cross-sectional study after a mean disease duration of 10.8+/-8.2 years (mean age 26.4+/-9.8 years). The occurrence of organ damage was measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Factors analysed as possible explanatory variables of organ damage were the following: demographic variables, clinical variables at diagnosis and during disease course, as well as medication use. Growth and self-reported health status were also measured.
The most frequent areas of organ damage were in the neuropsychiatric (28%), renal (13%) and musculoskeletal (13%) organ systems. Forty-three patients (61%) had evidence of damage. The mean SDI score was 1.3 for the whole study population. Hypertension, longer disease duration and use of cyclophosphamide were factors significantly related to an increasing SDI score in multiple linear regression analyses. Furthermore, patients with damage (SDI > or =1) compared to those without damage (SDI = 0) had a significantly higher cumulative corticosteroid dose (24.7 g versus 10.6 g) and more frequently required high-dose prednisolone at diagnosis (68% versus 43%).
Evidence of organ damage was found in 61% of all patients. Long disease duration, known hypertension and use of cylophosphamide were significantly associated with an increasing SDI score. Furthermore high-dose prednisolone at diagnosis and cumulative prednisolone dose were significantly related to the presence of organ damage.</description><subject>Adolescent</subject><subject>Age of Onset</subject><subject>Biological and medical sciences</subject><subject>Cross-Sectional Studies</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Female</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Health Status</subject><subject>Humans</subject><subject>Hypertension - etiology</subject><subject>Hypertension - pathology</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Lupus Nephritis - epidemiology</subject><subject>Lupus Nephritis - etiology</subject><subject>Lupus Nephritis - pathology</subject><subject>Lupus Vasculitis, Central Nervous System - epidemiology</subject><subject>Lupus Vasculitis, Central Nervous System - etiology</subject><subject>Lupus Vasculitis, Central Nervous System - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Musculoskeletal Diseases - epidemiology</subject><subject>Musculoskeletal Diseases - etiology</subject><subject>Musculoskeletal Diseases - pathology</subject><subject>Norway - epidemiology</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Severity of Illness Index</subject><subject>Time Factors</subject><issn>0392-856X</issn><issn>1593-098X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNpFkMtKxDAUhoMozjj6CpKNOwtN2qTpUsYrDLhRmN1wJjmdRnozJ0X6DL60xQuuDj__xw_fOWJLocosSUuzPWbLNCtlYpTeLtgZ0VuaSq10ccoWQplSlalcss9bTwiE3I0Bou-7a15PA4aIHc2JQ-d4i87b75IHfB99wBa7SBwCciDqrYeIjn_4WPM-HKDjDlo4IPcdt7VvXN33Luk7wshpooitt7wZh5E4hinW2ELsaaRzdlJBQ3jxe1fs9f7uZf2YbJ4fntY3m2SQWRmT3AqjCiew2ssSpFW5LqTNcgGp3RtX4GyMGmY9LQCl0hVoyJU00mGeK8xW7PJndxj3s9tuCL6FMO3-vjIDV78AkIWmCtBZT_-cNqnIhMm-ADX7cKw</recordid><startdate>20050301</startdate><enddate>20050301</enddate><creator>LILLEBY, V</creator><creator>FLATØ, B</creator><creator>FØRRE, Ø</creator><general>Clinical and Experimental Rheumatology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20050301</creationdate><title>Disease duration, hypertension and medication requirements are associated with organ damage in childhood-onset systemic lupus erythematosus</title><author>LILLEBY, V ; FLATØ, B ; FØRRE, Ø</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p239t-4c1857d1efb29a2c54672c341a0cb8d7e856e6a90261ae256fa6a45282de445e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adolescent</topic><topic>Age of Onset</topic><topic>Biological and medical sciences</topic><topic>Cross-Sectional Studies</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Female</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Health Status</topic><topic>Humans</topic><topic>Hypertension - etiology</topic><topic>Hypertension - pathology</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Lupus Nephritis - epidemiology</topic><topic>Lupus Nephritis - etiology</topic><topic>Lupus Nephritis - pathology</topic><topic>Lupus Vasculitis, Central Nervous System - epidemiology</topic><topic>Lupus Vasculitis, Central Nervous System - etiology</topic><topic>Lupus Vasculitis, Central Nervous System - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Musculoskeletal Diseases - epidemiology</topic><topic>Musculoskeletal Diseases - etiology</topic><topic>Musculoskeletal Diseases - pathology</topic><topic>Norway - epidemiology</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Severity of Illness Index</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LILLEBY, V</creatorcontrib><creatorcontrib>FLATØ, B</creatorcontrib><creatorcontrib>FØRRE, Ø</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LILLEBY, V</au><au>FLATØ, B</au><au>FØRRE, Ø</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Disease duration, hypertension and medication requirements are associated with organ damage in childhood-onset systemic lupus erythematosus</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2005-03-01</date><risdate>2005</risdate><volume>23</volume><issue>2</issue><spage>261</spage><epage>269</epage><pages>261-269</pages><issn>0392-856X</issn><eissn>1593-098X</eissn><abstract>To investigate the frequency of organ damage in childhood-onset systemic lupus erythematosus (SLE) and to identify disease variables and patient characteristics related to organ damage.
A cohort of 71 patients was examined in a cross-sectional study after a mean disease duration of 10.8+/-8.2 years (mean age 26.4+/-9.8 years). The occurrence of organ damage was measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Factors analysed as possible explanatory variables of organ damage were the following: demographic variables, clinical variables at diagnosis and during disease course, as well as medication use. Growth and self-reported health status were also measured.
The most frequent areas of organ damage were in the neuropsychiatric (28%), renal (13%) and musculoskeletal (13%) organ systems. Forty-three patients (61%) had evidence of damage. The mean SDI score was 1.3 for the whole study population. Hypertension, longer disease duration and use of cyclophosphamide were factors significantly related to an increasing SDI score in multiple linear regression analyses. Furthermore, patients with damage (SDI > or =1) compared to those without damage (SDI = 0) had a significantly higher cumulative corticosteroid dose (24.7 g versus 10.6 g) and more frequently required high-dose prednisolone at diagnosis (68% versus 43%).
Evidence of organ damage was found in 61% of all patients. Long disease duration, known hypertension and use of cylophosphamide were significantly associated with an increasing SDI score. Furthermore high-dose prednisolone at diagnosis and cumulative prednisolone dose were significantly related to the presence of organ damage.</abstract><cop>Pisa</cop><pub>Clinical and Experimental Rheumatology</pub><pmid>15895902</pmid><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0392-856X |
| ispartof | Clinical and experimental rheumatology, 2005-03, Vol.23 (2), p.261-269 |
| issn | 0392-856X 1593-098X |
| language | eng |
| recordid | cdi_pubmed_primary_15895902 |
| source | Freely Accessible Journals |
| subjects | Adolescent Age of Onset Biological and medical sciences Cross-Sectional Studies Cyclophosphamide - adverse effects Cyclophosphamide - therapeutic use Female Glucocorticoids - therapeutic use Health Status Humans Hypertension - etiology Hypertension - pathology Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Lupus Nephritis - epidemiology Lupus Nephritis - etiology Lupus Nephritis - pathology Lupus Vasculitis, Central Nervous System - epidemiology Lupus Vasculitis, Central Nervous System - etiology Lupus Vasculitis, Central Nervous System - pathology Male Medical sciences Musculoskeletal Diseases - epidemiology Musculoskeletal Diseases - etiology Musculoskeletal Diseases - pathology Norway - epidemiology Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Severity of Illness Index Time Factors |
| title | Disease duration, hypertension and medication requirements are associated with organ damage in childhood-onset systemic lupus erythematosus |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T07%3A50%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Disease%20duration,%20hypertension%20and%20medication%20requirements%20are%20associated%20with%20organ%20damage%20in%20childhood-onset%20systemic%20lupus%20erythematosus&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=LILLEBY,%20V&rft.date=2005-03-01&rft.volume=23&rft.issue=2&rft.spage=261&rft.epage=269&rft.pages=261-269&rft.issn=0392-856X&rft.eissn=1593-098X&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E15895902%3C/pubmed_pasca%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p239t-4c1857d1efb29a2c54672c341a0cb8d7e856e6a90261ae256fa6a45282de445e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/15895902&rfr_iscdi=true |